Search Results - "Rackl, E"

  • Showing 1 - 3 results of 3
Refine Results
  1. 1

    The potential role of serum extracellular vesicle derived small RNAs in AML research as non-invasive biomarker by Li, Lin, Mussack, Veronika, Görgens, André, Pepeldjiyska, Elena, Hartz, Anne Sophie, Aslan, Hazal, Rackl, Elias, Rank, Andreas, Schmohl, Jörg, El Andaloussi, Samir, Pfaffl, Michael W, Schmetzer, Helga

    Published in Nanoscale advances (14-03-2023)
    “…Background: Extracellular vesicles (EV) are cell-derived vesicles released by all cells in health and disease. Accordingly, EVs are also released by cells in…”
    Get full text
    Journal Article
  2. 2

    P07.02 Control leukemia by inducing anti-cancer immune reactivity in vivo? – Potential of a DC-triggered mechanism by Schmetzer, HM, Amberger, D, Klauer, L, Rackl, E, Atzler, M, Ugur, S, Plett, C, Rabe, A, Kugler, C, Rank, A, Baudrexler, T, Inngjerdingen, M, Eiz-Vesper, B, Schmid, C

    Published in Journal for immunotherapy of cancer (21-09-2022)
    “…BackgroundKit-M, the combination of response-modifiers GM-CSF+ Prostaglandine (PGE)1, converts myeloid blasts into dendritic cells(DC) of leukemic origin…”
    Get full text
    Journal Article
  3. 3

    P07.01 The potential role of extracellular vesicle-derived small RNAS in AML research as non-invasive biomarker by Li, L, Mussack, V, Görgens, A, Pepeldjiyska, E, Hartz, AS, Aslan, H, Rackl, E, Rank, A, Schmohl, J, Pfaffl, MW, Schmetzer, H

    Published in Journal for immunotherapy of cancer (21-09-2022)
    “…BackgroundAntileukemic responses of immune reactive cells in AML-patients need to be improved. Combinations of blast-modulatory kitM (GM-CSF+PGE1) (vs control)…”
    Get full text
    Journal Article